New drug could reduce hot flashes “by 72 percent”

First, what does “72% fewer hot flashes” actually mean?

Numbers in health headlines can be sneaky. A “72% reduction” doesn’t mean 72 out of 100 people were cured, or that your hot flashes will politely agree to only show up on weekends. In the study that sparked that figure, researchers tracked how often participants had hot flashes before and after taking an investigational drug. By day 3, the group taking the medication had about a 72% reduction in hot flash frequency compared with their own baseline.

Translation: if someone started with, say, 10 hot flashes a day, a 72% reduction could look like dropping to around 3 a dayfast. That’s the good news. The “read the fine print” news is that the number came from a controlled research setting with a relatively small sample size, and the drug in that early study (often referred to as pavinetant / MLE4901) did not ultimately become a mainstream prescription for hot flashes.

So why are people talking about it now? Because the science behind that resulttargeting a key brain pathwayhelped lead to today’s wave of modern nonhormonal menopause therapies, including medications that are approved and/or newly arriving.

The “malfunctioning thermostat” theory (and why it makes sense)

Hot flashes aren’t just “being warm.” They’re a rapid, body-wide response driven by the brain’s temperature control centerthink of it as a thermostat that suddenly becomes overly dramatic. During the menopause transition, estrogen levels change, and that shift affects a group of neurons in the hypothalamus that help regulate body temperature.

Many researchers focus on a specific neuron network commonly described as KNDy neurons (a name that sounds like a snack brand but is not, sadly, edible). These neurons communicate using substances including neurokinin B, which interacts with the NK3 receptor. When signaling gets dysregulated, the “temperature set point” narrows. Small changes that wouldn’t normally matterwarm coffee, a stressful email, a slightly stuffy roomcan trigger a full-body cooling response: flushing, sweating, and that classic “Who turned the sun on inside my chest?” sensation.

Here’s the key idea: if you can block the NK3 receptor signaling that’s contributing to this overreaction, you may reduce the frequency and severity of hot flasheswithout using hormones.

From “interesting research” to real prescriptions: the NK3 blocker era

For years, hormone therapy (estrogen with or without a progestogen, depending on whether someone has a uterus) has been the most effective treatment for vasomotor symptoms. But hormones aren’t a fit for everyoneespecially people with certain histories or risk profiles (for example, some cardiovascular issues, clotting risks, or estrogen-sensitive cancers). And even for people who can use hormones, some simply prefer a nonhormonal option.

That’s where NK3 receptor antagonists have changed the conversation. Instead of “more estrogen,” the approach is “calm the thermostat.”

Option 1: Veozah (fezolinetant) the first FDA-approved NK3 blocker

What it is

Fezolinetant (brand name Veozah) is a once-daily, nonhormonal prescription that blocks the NK3 receptor pathway involved in hot flashes. It became the first FDA-approved drug in this class for moderate to severe vasomotor symptoms due to menopause.

What the trials showed (in normal-human language)

In large phase 3 clinical trials, people taking fezolinetant generally saw a meaningful drop in the number of moderate-to-severe hot flashes compared with placebo during the first 12 weeks, and benefits were followed over longer periods in extension phases (up to a year total in those studies).

One practical way to imagine results is this: many participants weren’t going from “miserable” to “perfect,” but they were going from “hot flashes running my schedule” to “hot flashes are annoying but not the boss of me.” That shift can be huge for sleep, work, and sanity.

Who it might help most

• People with frequent, disruptive hot flashes and/or night sweats
• People who can’t or don’t want to use hormone therapy
• People looking for a targeted, nonhormonal option rather than “try this antidepressant and see”

Safety reality check: liver monitoring is part of the deal

Here’s the part that doesn’t fit neatly into a headline: fezolinetant requires liver testing. The FDA labeling includes a boxed warning related to hepatotoxicity risk in the postmarketing setting, and it instructs clinicians to check liver labs before starting and again on a schedule after initiation.

Practically, that means this isn’t a “grab it and forget it” medication. It’s more like “grab it, and also befriend your lab appointment scheduler.” The upside: monitoring is meant to catch problems early.

Common side effects (the boring but useful part)

People taking NK3 blockers may report side effects such as headache, sleep changes, gastrointestinal symptoms, or changes in liver enzymes. Not everyone gets side effects, but it’s important to discuss the full medication list (including over-the-counter products) with a clinician, because interactions can matter.

Option 2: Lynkuet (elinzanetant) a newer nonhormonal pill with “over 70%” trial reductions

What makes it different

Elinzanetant (brand name Lynkuet) is another nonhormonal medication designed to treat moderate to severe vasomotor symptoms. Like fezolinetant, it targets neurokinin signaling related to temperature regulation. It’s often described as a dual neurokinin-targeted therapy, and it has also been studied for potential sleep-related benefitsimportant, because night sweats don’t just ruin pajamas; they ruin mornings.

Where the “wow” numbers come from

In a yearlong phase 3 trial (OASIS-3), elinzanetant was associated with a rapid and significant reduction in hot flashes and night sweats. Reports from the study describe reductions in symptom frequency and severity that were notably larger than placebo by week 12, and the benefits appeared sustained over time.

This is where headlines start tossing around “over 70%” reductions. The key is to remember: placebo also reduces hot flashes in many trials because symptoms fluctuate naturally and because expectation effects are real. The meaningful question is not “Did the number look big?” but “How much better was it than placebo, and how safe is it over time?”

Side effects and practical considerations

Trial participants reported adverse effects such as headache and sleepiness. That “sleepiness” piece can be a pro or a con depending on your life. If you’re waking up drenched at 2:00 a.m., a medication that supports sleep may sound lovely. If you’re already fighting daytime fatigue, you’ll want to discuss timing, dose, and how your body reacts.

So… is the “72% hot flash reduction” claim true?

It’s rooted in real researchspecifically an earlier NK3 receptor antagonist study where hot flash frequency dropped quickly and dramatically compared with baseline. That result helped validate the biology and accelerated development of the newer class of treatments.

But the smartest way to read it is like this: “This pathway can be targeted successfully, and the effect can be large.” Not: “Everyone will get exactly 72% fewer hot flashes.”

Modern NK3-targeting drugs have stronger evidence bases, larger studies, longer follow-up, and real regulatory scrutinyplus real-world monitoring requirements. That’s progress.

How these new drugs compare with other hot flash treatments

Hormone therapy: still the heavy hitter (when appropriate)

Hormone therapy remains the most effective treatment for vasomotor symptoms for many people, especially when started within the appropriate window and when there are no contraindications. It can also improve other menopause-related symptoms. But it’s not one-size-fits-all, and risk/benefit discussions are personal.

Older nonhormonal options: helpful, but not always targeted

Before NK3 antagonists, nonhormonal options often meant using medications originally designed for something else, such as:

• Low-dose paroxetine (an SSRI) approved for vasomotor symptoms
• Other SSRIs/SNRIs sometimes used off-label for hot flashes
• Gabapentin (often used for nerve pain or seizures) sometimes used off-label, especially at night
• Clonidine (a blood pressure medication) used less often due to side effects

These can workand for some people they work very wellbut they may not be as directly aimed at the “thermostat” mechanism.

Behavioral and lifestyle strategies: underrated supporting actors

Lifestyle changes usually won’t erase severe hot flashes, but they can make the day-to-day less brutal: lightweight layers, cool bedroom setups, limiting alcohol if it’s a trigger, and stress management. Some approaches like cognitive behavioral therapy can help reduce how disruptive symptoms feel even if frequency doesn’t drop dramatically. Think of these as the “seatbelt” even if medication is the “airbag.”

Who should consider an NK3-targeting drug?

The best candidates are typically people with moderate to severe vasomotor symptoms that impair sleep, work, mood, or quality of lifeespecially if hormone therapy isn’t desired or isn’t recommended.

These medications also make sense for people who tried an SSRI/SNRI or gabapentin and either didn’t get enough relief or didn’t tolerate the side effects. In other words: if you’ve already played medication roulette and you’re tired of spinning the wheel, a targeted mechanism can be appealing.

What should slow someone down? Liver concerns, significant medication interactions, and any history that makes monitoring complicated. This is where a clinician’s guidance matters, because the decision isn’t just “Do I want fewer hot flashes?” It’s “Do I want fewer hot flashes in a way that fits my overall health picture?”

Bottom line: headline hype vs. real hope

The “72%” figure is a real data point from early NK3 receptor research, and it helped kick open the door to a new era of nonhormonal menopause treatments. Today, the conversation is less about one dramatic number and more about having multiple credible optionswith different mechanisms, different monitoring needs, and different trade-offs.

• Yes, hot flashes can be dramatically reduced with NK3-targeting drugs in clinical studies.
• Yes, these treatments can be life-changingespecially for sleep and daily function.
• Also yes, safety monitoring (especially liver labs for some medications) is part of responsible use.

If hot flashes are making life smallerskipping events, losing sleep, avoiding exercise, or feeling embarrassed at worktalking with a qualified clinician about both hormonal and nonhormonal options is not “being dramatic.” It’s being practical.

Medical note: This article is for general education and isn’t medical advice. Decisions about menopause treatment should be made with a licensed healthcare professional.

Experience Notes: What it can feel like when hot flashes meet a “new pill” plan

To be clear, everyone’s menopause journey is uniqueand no medication experience is universal. But there are some common patterns people describe when they go from “white-knuckling it” to trying a structured, modern treatment plan (especially with newer nonhormonal options).

Week 0: The countdown era. Many people don’t realize how much mental energy hot flashes consume until they start tracking them. You might notice the “predictable unpredictability”: the spike during a stressful meeting, the flare after a glass of wine, the 3:00 a.m. wake-up that turns into a full wardrobe change. It’s not just heatit’s planning. You plan outfits around ventilation. You plan seating around fans. You plan your life around exits. When symptoms are severe, it can feel like your body is hijacking your calendar.

The first few days: Is this placebo or is this real? When people start a new medication, the first question isn’t always “Is it working?” It’s “Am I imagining this?” That’s partly because placebo effects are real, but also because symptoms naturally vary. A good approach is to track baseline for a week or two before treatment, then keep tracking afterbecause memory is emotional, and hot flashes are loud. A simple log (frequency + severity + nighttime awakenings) can make changes easier to see.

The quiet win: sleeping through the night. A lot of people report that the biggest quality-of-life upgrade isn’t even daytime comfortit’s sleep. Night sweats can wreck rest in sneaky ways: waking up hot, waking up damp, waking up annoyed, then waking up again because now you’re cold. When symptoms ease, the victory can be subtle: fewer awakenings, less tossing, fewer “Why am I awake?” spirals. And once sleep improves, many people feel more resilient during the day. The same stressor that used to trigger a hot flash can become… just a stressor. Still annoying, but not thermonuclear.

The practical reality: labs and logistics. Newer nonhormonal options can come with monitoring. People often describe the initial “Wait, I have to do what?” reactionthen the adjustment to a routine: schedule labs, set reminders, pair check-ins with something pleasant (coffee with a friend, a walk afterward), and treat the process like responsible maintenance, not punishment. It’s not glamorous, but it’s manageableand for many, worth it.

The honest middle: not perfect, but better. Some people expect a medication to erase hot flashes completely. When that doesn’t happen, disappointment can creep in. But many describe a different outcome that still feels like freedom: fewer episodes, less intensity, shorter duration, and less “aftershock” anxiety. A hot flash that used to dominate ten minutes might become a quick wave you can breathe through without rearranging your entire day.

The long-game mindset: The most satisfied experiences tend to come from people who treat symptom relief like a toolkit, not a single lever. Medication helps. Sleep hygiene helps. Cooling strategies help. Knowing triggers helps. Stress reduction helps. And having language to explain what’s happening (“This is a vasomotor symptom, not me ‘being weird’”) helps more than anyone expects.

If the “72%” headline got your attention, that’s understandable. But the real story is bigger: science is finally treating hot flashes like a serious, biologically grounded problemwith multiple solutions that can be matched to different lives.